Thank you for Subscribing to Life Science Review Weekly Brief
Nirrin Technologies can overcome several challenges of traditional process analytical technologies (PAT) with Gamma Biosciences’ strategic and commercial resources.
FREMONT, CA: “We are excited to enter the next phase of the Nirrin journey alongside Gamma Biosciences as we empower upstream and downstream biomanufacturing with accurate and instantaneous real-time process data,” states Bryan Hassell, Founder and CTO of Nirrin. Gamma Biosciences makes a strategic investment in Nirrin Technologies, a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications for the biopharma and life science industries.
Gamma Biosciences and its operating companies have agreed to invest in Nirrin, giving it access to their strategic and commercial resources. Customer engagements with premier developers and producers of advanced medicines, such as cell and gene therapies, biologics, and vaccines, will be expanded.
Nirrin's platform is based on a highly adaptable, tunable laser-based technology that overcomes many of the drawbacks of traditional process analytical technologies (PAT), which rely on sampling and off-line analysis or proxy sensors that measure surrogate analytes to foretell bioprocessor performance.
Nirrin's products enable various plug-and-play applications, including real-time glucose monitoring and control, cumulative and viable cell density in-line measurements, and downstream protein concentration and aggregation by combining modified near-infrared spectroscopy with powerful back-end data processing.
“With continued validation and adoption of our platform, we are on track to offer the most effective solution for downstream protein and formulation analysis, and the only platform capable of reliable, real-time glucose measurement for upstream cell culture,” Hassell adds.
“We are thrilled to partner with the Nirrin team to tap into the rapidly growing demand for critical, real-time data for analytics and process control,” comments Phil Vanek, CTO of Gamma Biosciences. “The rich data generated by Nirrin’s sensor and analytics suite is a game-changer for the application of data science and machine learning to optimize process scale up and cell engineering. With immediate applications for cell therapy and mAb manufacturing, and potential for gene therapy and industrial biotech, we are looking forward to bringing this powerful technology to the market.”